Maintenance Percutaneous Posterior Nerve Stimulation for Refractory Lower Urinary Tract Symptoms in Patients with Multiple Sclerosis: An Open Label, Multicenter, Prospective Study

2014 ◽  
Vol 191 (3) ◽  
pp. 697-702 ◽  
Author(s):  
C. Zecca ◽  
G.A. Digesu ◽  
P. Robshaw ◽  
A. Singh ◽  
S. Elneil ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Urinary Tract ◽  
Prospective Study ◽  
Lower Urinary Tract Symptoms ◽  
Nerve Stimulation ◽  
Lower Urinary Tract ◽  
Open Label ◽  
Urinary Tract Symptoms ◽  
Multicenter Prospective Study ◽  
Lower Urinary

Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial

2011 ◽  
Vol 17 (12) ◽  
pp. 1514-1519 ◽  
Author(s):  
C Gobbi ◽  
GA Digesu ◽  
V Khullar ◽  
S El Neil ◽  
G Caccia ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Nerve Stimulation ◽  
Lower Urinary Tract ◽  
Tibial Nerve ◽  
Tibial Nerve Stimulation ◽  
Urinary Tract Symptoms ◽  
The Mean ◽  
Lower Urinary

Background: Percutaneous tibial nerve stimulation (PTNS) has been proposed as a new, minimally invasive neuromodulation technique to treat lower urinary tract symptoms (LUTS). Objective: To evaluate efficacy, safety and impact on quality of life (QoL) of PTNS on patients with multiple sclerosis (MS) who have LUTS. Methods: 21 patients (5 men, 16 women) with MS and LUTS unresponsive to anticholinergics were treated with 12 sessions of PTNS. Assessment of LUTS was by validated, self-administered chart and questionnaires, testing the subjective and objective relevance of LUTS for patients and their impact on QoL before and after treatment; the mean post-micturition residual was assessed by trans-abdominal ultrasound scanning. Analysis was by intention to treat. Results: There was a significant reduction of daytime frequency (from 9 to 6, p = 0.04), nocturia (from 3 to 1, p = 0.002) and mean post-micturition residual (from 98 ± 124 ml to 43 ± 45 ml, p = 0.02). The mean voided volume increased from 182 ± 50 ml to 225 ± 50 ml ( p = 0.003). Eighty-nine percent of patients reported a treatment satisfaction of 70%. Significant improvement in QoL was seen in most domains of the King’s Health QoL questionnaire ( p < 0.05). No adverse events were reported. Conclusions: PTNS is an effective, safe and well-tolerated treatment for LUTS in patients with MS.

scholarly journals Surveying the Prevalence of Lower Urinary Tract Symptoms Based on Individual and Clinical Parameters in Patients with Multiple Sclerosis

2019 ◽  
Author(s):  
Fatemeh Nazari ◽  
Vahid Shaygannejad ◽  
Mehrdad Mohammadi Sichani ◽  
Marjan Mansourian Gharaagozlou ◽  
Valiollah Hajhashemi
Keyword(s):  
Multiple Sclerosis ◽  
Urinary Tract ◽  
Symptom Score ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Statistical Tests ◽  
Men And Women ◽  
Urinary Tract Symptoms ◽  
Significant Difference ◽  
Lower Urinary

Abstract Background Most patients with multiple sclerosis (MS) suffer from bladder dysfunction during the course of the disease. This study was conducted to examine the prevalence of these complications among patients with MS. Methods This cross-sectional study was performed on 603 patients with MS who referred to the neurology clinics of Kashani and Alzahra Hospitals affiliated to Isfahan University of Medical Sciences, Isfahan, Iran. The sampling was performed by multi-stage random cluster sampling method and the informed consent form was filled in by the subjects. Then, all the data were collected through interviews using the Lower Urinary Tract Symptom Score (LUTSS) developed in accordance with the definitions presented by the International Continence Society (ICS) and the International Prostate Symptom Score (I-PSS). The data were analyzed using descriptive and inferential statistical tests in SPSS and the significance level was considered to be less than 0.050. Results The prevalence rate of lower urinary tract symptoms (LUTS) was 87.6% among all the subjects, with a similar rate among women (88.0%) and men (86.0%). There was a significant difference between the two groups of men and women in terms of the prevalence of stress urinary incontinence (SUI), intermittent urine flow, hesitancy, straining, and dribbling (P < 0.050). There was no significant difference between the two groups of women and men in terms of the prevalence of other symptoms (P > 0.050). Moreover, there was a significant difference between the degree of LUTS with age, marital status, education, duration of illness, clinical course, and disability (P < 0.05). Conclusions A high prevalence of LUTS was found among patients with MS, with similar rates in men and women, and the nature of the urinary complaints and LUTS was different among men and women with MS. Therefore, it is recommended that the health system take necessary measures regarding timely detection and treatment of LUTS among these patients in order to prevent secondary outcomes and improve the quality of life (QOL) of patients with MS.

Sign in / Sign up

Export Citation Format

Share Document